Heptabarb: Difference between revisions
CSV import |
CSV import |
||
| Line 31: | Line 31: | ||
{{medicine-stub}} | {{medicine-stub}} | ||
{{No image}} | {{No image}} | ||
<gallery> | |||
File:Heptabarbital structure.svg|Heptabarb | |||
</gallery> | |||
<gallery> | <gallery> | ||
File:Heptabarbital structure.svg|Heptabarb | File:Heptabarbital structure.svg|Heptabarb | ||
</gallery> | </gallery> | ||
Revision as of 01:44, 20 February 2025
Heptabarb is a barbiturate derivative that was developed in the 1950s. It has sedative and hypnotic properties, and was used for the treatment of insomnia before being replaced by safer and more effective drugs. Heptabarb is now rarely used, and is not available in many countries due to its high potential for drug abuse and overdose.
Pharmacology
Heptabarb acts by enhancing the action of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABAA receptor, resulting in sedative, hypnotic (sleep-inducing), anxiolytic (anti-anxiety), anticonvulsant, and muscle relaxant properties. The exact mechanisms of action are complex and not fully understood.
Side effects
Common side effects of heptabarb include drowsiness, dizziness, and loss of coordination. More serious side effects can include confusion, hallucinations, and severe drowsiness or unconsciousness. Overdose can lead to respiratory depression and death.
History
Heptabarb was first synthesized in the 1950s as part of a series of barbiturate derivatives. It was used for several decades as a treatment for insomnia, but has largely been replaced by newer drugs with fewer side effects and lower potential for abuse and overdose.
See also
References
<references />
-
Heptabarb
-
Heptabarb
